BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18391984)

  • 1. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
    Cornforth AN; Davis JS; Khanifar E; Nastiuk KL; Krolewski JJ
    Oncogene; 2008 Jul; 27(32):4422-33. PubMed ID: 18391984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis.
    Raclaw KA; Heemers HV; Kidd EM; Dehm SM; Tindall DJ
    Prostate; 2008 Nov; 68(15):1696-706. PubMed ID: 18726983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells.
    Wilson C; Wilson T; Johnston PG; Longley DB; Waugh DJ
    Mol Cancer Ther; 2008 Sep; 7(9):2649-61. PubMed ID: 18790747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
    Yang L; Xie S; Jamaluddin MS; Altuwaijri S; Ni J; Kim E; Chen YT; Hu YC; Wang L; Chuang KH; Wu CT; Chang C
    J Biol Chem; 2005 Sep; 280(39):33558-65. PubMed ID: 16061480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
    Zhang X; Li W; Olumi AF
    Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells.
    Kadowaki Y; Chari NS; Teo AE; Hashi A; Spurgers KB; McDonnell TJ
    Apoptosis; 2011 Jun; 16(6):627-35. PubMed ID: 21437722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).
    Li W; Zhang X; Olumi AF
    Cancer Res; 2007 Mar; 67(5):2247-55. PubMed ID: 17332355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation.
    Lynch RL; Konicek BW; McNulty AM; Hanna KR; Lewis JE; Neubauer BL; Graff JR
    Mol Cancer Res; 2005 Mar; 3(3):163-9. PubMed ID: 15798096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.
    Yun H; Xie J; Olumi AF; Ghosh R; Kumar AP
    Oncotarget; 2015 May; 6(13):11600-13. PubMed ID: 25816367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-alpha-dependent apoptosis.
    Giampietri C; Petrungaro S; Padula F; D'Alessio A; Marini ES; Facchiano A; Filippini A; Ziparo E
    Apoptosis; 2012 Nov; 17(11):1210-22. PubMed ID: 22923157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.
    Gao S; Lee P; Wang H; Gerald W; Adler M; Zhang L; Wang YF; Wang Z
    Mol Endocrinol; 2005 Jul; 19(7):1792-802. PubMed ID: 15731171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
    Zhang T; Wang X; He D; Jin X; Guo P
    Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.
    Alladina SJ; Song JH; Davidge ST; Hao C; Easton AS
    J Vasc Res; 2005; 42(4):337-47. PubMed ID: 15985761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.
    Murillo H; Huang H; Schmidt LJ; Smith DI; Tindall DJ
    Endocrinology; 2001 Nov; 142(11):4795-805. PubMed ID: 11606446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
    Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF
    Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
    Peuhu E; Rivero-Müller A; Stykki H; Torvaldson E; Holmbom T; Eklund P; Unkila M; Sjöholm R; Eriksson JE
    Oncogene; 2010 Feb; 29(6):898-908. PubMed ID: 19935713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells.
    Park SJ; Sohn HY; Yoon J; Park SI
    Cell Signal; 2009 Oct; 21(10):1495-503. PubMed ID: 19470406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer.
    Ye H; Li Y; Melamed J; Pearce P; Wei J; Chiriboga L; Wang Z; Osman I; Lee P
    J Urol; 2009 Feb; 181(2):872-7. PubMed ID: 19095249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.
    McCourt C; Maxwell P; Mazzucchelli R; Montironi R; Scarpelli M; Salto-Tellez M; O'Sullivan JM; Longley DB; Waugh DJ
    Clin Cancer Res; 2012 Jul; 18(14):3822-33. PubMed ID: 22623731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.